Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.

Maryann KwaXiaochun LiYelena NovikRuth OratzKomal JhaveriJennifer WuPing GuMarleen MeyersFranco MuggiaJames SpeyerAlyssa IwanoMaryam BonakdarLina KozhayaEce TavukcuogluBahar BudanRoy RaadJudith D GoldbergDerya UnutmazSylvia Adams

Published in: Breast cancer research and treatment (2017)

Treg depletion was not observed with low-dose cyclophosphamide when assessed by the specific marker FOXP3 + Helios +; however, baseline naïve Tregs were associated with 3-month PFS. Exemestane/cyclophosphamide combination had favorable safety profile with evidence of clinical activity in heavily pretreated patients.

Keyphrases

low dose
high dose
positive breast cancer
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
regulatory t cells
peritoneal dialysis
prognostic factors
metastatic breast cancer
clinical trial
randomized controlled trial
dendritic cells